Precigen (Formerly Intrexon)
Biologically-based products that improve the quality of life and the health of the planet.
Launch date
Employees
Market cap
€264m
Enterprise valuation
€252m (Public information from Sep 2024)
Share price
$1.04 PGEN
Germantown Maryland (HQ)
Notable known LPs: Great American Life Insurance, Great American Insurance Group
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 103m | 104m | 26.9m | 6.2m | 4.4m | 22.3m | 224m |
| % growth | 14 % | 1 % | (74 %) | (77 %) | (29 %) | 403 % | 903 % |
| EBITDA | (84.5m) | (77.5m) | (72.1m) | (78.4m) | - | - | - |
| % EBITDA margin | (82 %) | (75 %) | (268 %) | (1259 %) | - | - | - |
| Profit | (171m) | (92.2m) | 28.3m | (95.9m) | (125m) | (71.9m) | 70.9m |
| % profit margin | (165 %) | (89 %) | 105 % | (1541 %) | (2817 %) | (322 %) | 32 % |
| EV / revenue | 19.0x | 8.0x | 9.7x | 43.5x | 67.2x | 12.1x | 1.4x |
| EV / EBITDA | -23.2x | -10.8x | -3.6x | -3.5x | - | - | - |
| R&D budget | 41.6m | 50.1m | 47.2m | 48.6m | - | - | - |
| R&D % of revenue | 40 % | 48 % | 175 % | 781 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$25.0m | Series C | ||
$10.0m | Series C | ||
| N/A | $17.4m | Series D | |
$100m | Series E | ||
$150m | Series F | ||
| N/A | N/A | IPO | |
| N/A | $57.5m | Post IPO Equity | |
| N/A | $35.0m | Post IPO Equity | |
* | N/A | $129m | Post IPO Equity |
* | N/A | $75.0m | Post IPO Equity |
| Total Funding | €276m | ||
